William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX gives an overview of his poster on the ‘Management of transaminase elevations in patients receiving idelalisib’ in chronic lymphocytic leukemia (CLL) presented at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. According to Dr Wierda, transaminitis can be seen in patients who are initiating on idelalisib after approximately 2-4 weeks and is usually reversible. The management of this side effect is important in order to avoid damage to the liver.